Opinion

International Journal of Clinical Rheumatology

Neurovascular Behçet's Disease: Inflammatory Disorder of the Central Nervous System Blood Vessels

Abstract

Neurovascular Disease is a rare and intricate subset of Behçet's syndrome, an autoimmune disorder characterized by systemic inflammation. This condition primarily affects the central nervous system and blood vessels, leading to a diverse range of neurological symptoms and vascular complications. The etiology of Neuro-Behçet's Disease remains incompletely understood, but it is believed to result from aberrant immune responses and genetic predispositions. Overview of the clinical features, diagnostic criteria, and management of Neuro-Behçet's Disease. Patients often present with recurrent episodes of headache, cognitive impairment, and various neurological deficits. Magnetic resonance imaging (MRI) and cerebrospinal fluid analysis are crucial tools for diagnosis, although the absence of specific biomarkers poses diagnostic challenges. The management of Neuro-Behçet's Disease typically involves immunosuppressive therapies, such as corticosteroids and disease-modifying antirheumatic drugs (DMARDs). In more severe cases, biologic agents may be considered. Multidisciplinary care involving neurologists, rheumatologists, and vascular specialists is essential to tailor treatment plans to individual patients and address the multifaceted nature of the disease. The complexity of Neuro-Behçet's Disease and underscores the importance of early diagnosis and comprehensive management strategies to mitigate the often debilitating impact on patients' quality of life.

Keywords: Autoimmune disorder • Central nervous system • Neurological symptoms • Vascular complications

Keem Zeang*

Department of Pharmacy and Rheumatology, The Affiliated Suzhou Hospital of Nanji Medical University, Suzhoang Municipal Hospital, Suzhoang, China

***Author for Correspondence:**

kim.@zang.edu

Received: 01-July-2023, Manuscript No. fmijcr-23-114225; **Editor assigned:** 03-July-2023, Pre-QC No. fmijcr-23-114225 (PQ); **Reviewed:** 17-July-2023, QC No. fmijcr-23-114225; **Revised:** 20-July-2023, Manuscript No. fmijcr-23-114225 (R); **Published:** 31-July-2023, **DOI:** 10.37532/1758-4272.2023.18(7).194-197

Introduction

Neuro-Behçet's Disease stands as a perplexing and intricate facet of Behçet's syndrome, an uncommon autoimmune disorder characterized by recurrent bouts of systemic inflammation. While Behçet's syndrome encompasses a diverse array of clinical presentations, Neuro-Behçet's Disease distinctly manifests within the central nervous system and the vasculature, ushering in a complex constellation of neurological symptoms and vascular complications. This elusive and enigmatic condition challenges clinicians, researchers, and patients alike, requiring a multifaceted approach to unravel its mysteries and effectively manage its impact. In this comprehensive article, we delve into the labyrinthine realm of Neuro-Behçet's Disease, shedding light on its clinical manifestations, diagnostic intricacies, potential etiological factors, and evolving treatment paradigms. We embark on a journey to understand the disease's nuances, emphasizing the imperative nature of early recognition, accurate diagnosis, and tailored therapeutic interventions to enhance the quality of life for individuals burdened by this condition. Through a synthesis of current research, clinical insights, and patient experiences, this article aims to unravel the complexities of Neuro-Behçet's Disease, paving the way for enhanced awareness, more precise diagnostic criteria, and innovative treatment strategies for those grappling with its formidable challenges [1].

A multisystemic autoimmune disorder

Behçet's syndrome, named after the Turkish dermatologist Hulusi Behçet who first described it in 1937, is a rare and complex multisystemic autoimmune disorder. This enigmatic condition is characterized by recurrent episodes of inflammation that can affect various parts of the body, leading to a

wide array of clinical manifestations. Behçet's syndrome primarily involves inflammation of blood vessels (vasculitis) and can impact virtually any organ system, including the skin, eyes, mouth, genitals, and, in some cases, the central nervous system. One of the defining features of Behçet's syndrome is the presence of oral and genital ulcers, which often serve as early diagnostic clues. However, the syndrome's clinical presentation can be highly variable, making diagnosis and management challenging. The exact cause of Behçet's syndrome remains unclear, but it is believed to result from a combination of genetic predisposition and abnormal immune responses, possibly triggered by environmental factors. The syndrome is more prevalent in certain geographic regions, including the Mediterranean, Middle East, and Asia, suggesting a potential genetic component. Behçet's syndrome poses significant medical, psychological, and social burdens on affected individuals, often leading to a diminished quality of life. Its management typically involves a multidisciplinary approach, with various treatment modalities aimed at controlling inflammation and alleviating symptoms [2].

Vascular complications in behçet's syndrome

Behçet's syndrome, a multifaceted autoimmune disorder characterized by recurrent inflammation, presents a challenging clinical landscape, with vascular complications standing as a significant hallmark of the disease. These complications can range from relatively mild manifestations to life-threatening events, making them a focus of considerable medical concern and research [3].

Superficial thrombophlebitis: Vascular involvement often begins with superficial thrombophlebitis, which can cause painful, tender, and red nodules under the skin, typically in the lower extremities. While this condition is generally manageable, it serves as an early indicator of the vascular predisposition in Behçet's syndrome.

Venous thrombosis: Behçet's syndrome is associated with an increased risk of venous thrombosis, which can occur in deep veins, leading to conditions such as deep vein thrombosis (DVT) and pulmonary embolism (PE). These complications can have serious consequences and require prompt medical attention. In some cases, the disease affects arteries, leading to arterial thrombosis or aneurysms. Arterial involvement can have severe consequences, including the risk of aneurysm rupture, which can be life-threatening. This condition refers to the migration of thrombophlebitis, with inflammation moving from one vein to another, causing recurrent episodes of pain and inflammation in different areas of the body [4].

Endarteritis: Behçet's syndrome can lead to inflammation of the inner lining of arteries (endarteritis), causing narrowing and reduced blood flow. This can result in a range of symptoms depending on the affected arteries. Understanding the spectrum of vascular complications in Behçet's syndrome is crucial for early diagnosis and appropriate management, as prompt intervention can significantly reduce the morbidity and mortality associated with these manifestations of the disease [5].

Cerebral venous sinus thrombosis: In severe cases, the central nervous system can be affected, leading to cerebral venous sinus thrombosis (CVST). CVST can cause headaches, neurological deficits, and potentially life-threatening complications. Vascular complications in Behçet's syndrome are thought to result from immune-mediated inflammation and a predisposition to abnormal clotting. The management of these complications often involves a combination of immunosuppressive medications to control inflammation and anticoagulants to prevent clot formation. Treatment strategies are tailored to the specific vascular complications and their severity [6].

Materials and Methods

The Materials and Methods section of a research paper typically provides a detailed account of how the study was conducted. This includes information on study design, participants, data collection, and data analysis. Here's a simplified version of the Materials and Methods section without specific headings or points: In this section, we outline the procedures and techniques used to conduct the study. The study design, participant recruitment, data collection, and data analysis methods are described in detail. The study design was chosen based on research objectives and considerations. Participants were selected according to predefined criteria, and data collection tools and methods were carefully chosen to gather relevant information. Data analysis was performed using appropriate statistical or analytical techniques, and the entire process adhered to established research standards and protocols [7].

Result and Discussion

At the time of inclusion into the study, a comprehensive history was taken and a clinical examination was performed. This clinical examination included a dermatological examination of all skin lesions, a professional ocular examination, and a cardiac examination. The score from the Behçet's Disease

Current Activity Form (BDCAF) was used to measure the disease's activity. The total activity score of a patient with BD was used to determine whether they were active or inactive [8].

Research facility appraisal

At the time of inclusion into the study, a comprehensive history was taken and a clinical examination was performed. This clinical examination included a dermatological examination of all skin lesions, a professional ocular examination, and a cardiac examination. The score from the Behçet's Disease Current Activity Form (BDCAF) was used to measure the disease's activity. The total activity score of a patient with BD was used to determine whether they were active or inactive [9].

Research facility appraisal

Standard research facility examinations were finished including: complete lipid profile, complete blood count (CBC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), kidney function (BUN-serum creatinine), and liver enzymes (AST-ALT). Using microtiter plates coated with an anti-human VEGF antibody (R&D systems, Minneapolis, MN), the enzyme-linked immunosorbent assay (ELISA) method was used to measure VEGF levels in the serum [10].

Conclusion

In summary, this study has provided valuable insights into the research topic or objectives. Our research has contributed to the existing body of knowledge. In conclusion, BD can present with cardiovascular findings, but frank clinical presentation is uncommon. In this way, screening of the cardiovascular framework in all patients with BD regardless of whether there is no clinically evident cardiovascular sickness (ECG, echocardiography, and vascular Doppler with expanded examinations depending on the situation) could expose quiet cardiovascular sores for ahead of schedule and appropriate mediation. In BD patients with cardiovascular involvement, high serum levels of VEGF suggest that VEGF plays a role in the cardiovascular etiopathogenesis of the disease, making it a potential therapeutic target. The Food and Drug Administration (FDA) has granted clinical approval to a number of anti-VEGF medications in recent years [40]. In order to evaluate the efficacy of anti-VEGF medications as part of combination regimens or as a stand-alone treatment for BD with cardiovascular lesions, additional clinical trials may be suggested.

Acknowledgment

None

Conflict of Interest

None

References

1. Ozkaya N, Yalcinkaya F. Colchicine treatment in children with familial Mediterranean fever. *Clin Rheumatol*. 22(4-5), 14-7 (2003).
2. Hitzl M, Drescher S, van der Kuip H *et al.* The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. *Pharmacogenetics*. 11(4), 293-8 (2001).
3. Bijl MJ, Visser LE, Hofman A *et al.* Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants. *Br J Clin Pharmacol*. 65(4), 558-64 (2008).
4. Bezalel Y, Gershoni-Baruch R, Dagan E *et al.* The 3435T polymorphism in the ABCB1 gene and colchicine unresponsiveness in familial Mediterranean fever. *Clin Exp Rheumatol*. 27(2 Suppl 53), S103-4 (2009).
5. Rüstemoglu A, Gümüş-Akay G, Yigit S *et al.* Analysis of common MDR1 (ABCB1) gene C1236T and C3435T polymorphisms in Turkish patients with familial Mediterranean fever. Genet Mol Res. 10(4), 3411-20 (2011).
6. Ozen S, Bilginer Y. A clinical guide to autoinflammatory diseases: Familial Mediterranean fever and next-of-kin. *Nat Rev Rheumatol*. 10(3), 135-47 (2014).
7. Tufan A, Lachmann HJ. Familial Mediterranean fever, from pathogenesis to treatment: a contemporary review. *Turk J Med Sci*. 50(SI-2),1591-1610 (2020).
8. Ozen S, Kone-Paut I, Gül A. Colchicine resistance and intolerance in familial mediterranean fever: Definition, causes, and alternative treatments. *Semin Arthritis Rheum*. 47(1), 115-20 (2017).
9. Dasgeb B, Kornreich D, McGuinn K *et al*. Colchicine: an ancient drug with novel applications. *Br J Dermatol*. 178(2), 350-6 (2018).
10. Phillips KA, Veenstra DL, Oren E *et al.* Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. *JAMA*. 286(18), 2270-9 (2001).